Thus, the frequently observed haploinsufficiency of NKX3.1 in prostate cancer may significantly contribute to the activation of ERG protooncogene in the TMPRSS2-ERG fusion genomic context. This evidence concerns the gene NKX3-1 and prostate cancer.